Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Senescent cells: a therapeutic target for cardiovascular disease
Bennett G. Childs, … , Hu Li, Jan M. van Deursen
Bennett G. Childs, … , Hu Li, Jan M. van Deursen
Published April 2, 2018
Citation Information: J Clin Invest. 2018;128(4):1217-1228. https://doi.org/10.1172/JCI95146.
View: Text | PDF
Review Series

Senescent cells: a therapeutic target for cardiovascular disease

  • Text
  • PDF
Abstract

Cellular senescence, a major tumor-suppressive cell fate, has emerged from humble beginnings as an in vitro phenomenon into recognition as a fundamental mechanism of aging. In the process, senescent cells have attracted attention as a therapeutic target for age-related diseases, including cardiovascular disease (CVD), the leading cause of morbidity and mortality in the elderly. Given the aging global population and the inadequacy of current medical management, attenuating the health care burden of CVD would be transformative to clinical practice. Here, we review the evidence that cellular senescence drives CVD in a bimodal fashion by both priming the aged cardiovascular system for disease and driving established disease forward. Hence, the growing field of senotherapy (neutralizing senescent cells for therapeutic benefit) is poised to contribute to both prevention and treatment of CVD.

Authors

Bennett G. Childs, Hu Li, Jan M. van Deursen

×

Figure 3

Senescent cells drive heart failure.

Options: View larger image (or click on image) Download as PowerPoint
Senescent cells drive heart failure.
(A) In young hearts, myocardium hom...
(A) In young hearts, myocardium homeostasis, normal tissue function, and excess cardiac reserve are maintained through de novo formation of cardiomyocytes from resident cardiomyocyte stem cells (CMSCs) or division of incompletely differentiated, small cardiomyocytes. New cardiomyocyte formation matches a relatively low rate of cardiomyocyte apoptosis (purple cells). Appropriate CMSC function, including return to quiescence and suppression of cardiomyocyte death, may be maintained by homeostatic signals arising from the pericardium. (B) In disease-free, aging hearts, a declining ability to replace apoptotic cardiomyocytes due to progenitor dysfunction/senescence conspires with an increasing rate of cardiomyocyte death to produce compensatory hypertrophy. In the resting state and in the absence of further CVD, this adaptive change partially preserves heart function but predisposes to heart failure upon further stress. Interestingly, the INK-ATTAC SNC-killing transgenic strategy efficiently removes SA β-gal–positive pericardial SNCs from aged mice and prevents both cardiomyocyte hypertrophy and declining β-adrenergic stress tolerance. Based on this, we propose the existence of pericardium-derived prohomeostatic signaling that is disrupted during aging by pericardial SASP factors, although similar disruptive signaling may arise from senescent cardiomyocytes, CMSCs, or other cell types in the myocardium. (C) When challenged with cardiovascular stressors, such as ischemia in coronary artery disease, diabetes, or hypertension, the aged myocardium exceeds its functional reserve and decompensates. Apoptotic cardiomyocytes are not replaced, hypertrophy no longer preserves function, and excessive fibrosis leads to conduction defects, arrhythmia, and HF. To some extent, fibroblast senescence restricts fibrosis, but the long-term presence of these and other SNC types in the failing heart is suspected to be deleterious. It is currently unclear whether SNC removal can improve established heart failure or merely blunts development.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts